| Psychological treatments in schizophrenia: I. Meta-analysis of family intervention and cognitive behaviour therapy S Pilling, P Bebbington, E Kuipers, P Garety, J Geddes, G Orbach, ... Psychological medicine 32 (5), 763-782, 2002 | 1273 | 2002 |
| Ketamine use: a review CJA Morgan, HV Curran, ... Addiction 107 (1), 27-38, 2012 | 765 | 2012 |
| Psychological treatments in schizophrenia: II. Meta-analyses of randomized controlled trials of social skills training and cognitive remediation S Pilling, P Bebbington, E Kuipers, P Garety, J Geddes, B Martindale, ... Psychological medicine 32 (5), 783-791, 2002 | 568 | 2002 |
| Keep off the grass? Cannabis, cognition and addiction HV Curran, TP Freeman, C Mokrysz, DA Lewis, CJA Morgan, LH Parsons Nature Reviews Neuroscience 17 (5), 293-306, 2016 | 476 | 2016 |
| Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis CJA Morgan, HV Curran The British Journal of Psychiatry 192 (4), 306-307, 2008 | 405 | 2008 |
| Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study CJA Morgan, G Schafer, TP Freeman, HV Curran The British Journal of Psychiatry 197 (4), 285-290, 2010 | 404 | 2010 |
| Consequences of chronic ketamine self‐administration upon neurocognitive function and psychological wellbeing: a 1‐year longitudinal study CJA Morgan, L Muetzelfeldt, HV Curran Addiction 105 (1), 121-133, 2010 | 380 | 2010 |
| Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers CJA Morgan, A Mofeez, B Brandner, L Bromley, HV Curran Neuropsychopharmacology 29 (1), 208-218, 2004 | 358 | 2004 |
| Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later HV Curran, C Morgan Addiction 95 (4), 575-590, 2000 | 348 | 2000 |
| Acute and chronic effects of ketamine upon human memory: a review CJA Morgan, HV Curran Psychopharmacology 188, 408-424, 2006 | 341 | 2006 |
| Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors A Demjaha, JM Lappin, D Stahl, MX Patel, JH MacCabe, OD Howes, ... Psychological medicine 47 (11), 1981-1989, 2017 | 305 | 2017 |
| Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms MAP Bloomfield, CJA Morgan, A Egerton, S Kapur, HV Curran, OD Howes Biological psychiatry 75 (6), 470-478, 2014 | 270 | 2014 |
| Journey through the K-hole: phenomenological aspects of ketamine use L Muetzelfeldt, SK Kamboj, H Rees, J Taylor, CJA Morgan, HV Curran Drug and alcohol dependence 95 (3), 219-229, 2008 | 264 | 2008 |
| Cannabidiol attenuates the appetitive effects of Δ9-tetrahydrocannabinol in humans smoking their chosen cannabis CJA Morgan, TP Freeman, GL Schafer, HV Curran Neuropsychopharmacology 35 (9), 1879-1885, 2010 | 263 | 2010 |
| Cannabidiol enhances consolidation of explicit fear extinction in humans RK Das, SK Kamboj, M Ramadas, K Yogan, V Gupta, E Redman, ... Psychopharmacology 226, 781-792, 2013 | 246 | 2013 |
| Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being CJA Morgan, C Gardener, G Schafer, S Swan, C Demarchi, TP Freeman, ... Psychological medicine 42 (2), 391-400, 2012 | 244 | 2012 |
| Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings CJA Morgan, RK Das, A Joye, HV Curran, SK Kamboj Addictive behaviors 38 (9), 2433-2436, 2013 | 232 | 2013 |
| Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis … C Hindocha, TP Freeman, G Schafer, C Gardener, RK Das, CJA Morgan, ... European Neuropsychopharmacology 25 (3), 325-334, 2015 | 207 | 2015 |
| Ketamine use, cognition and psychological wellbeing: a comparison of frequent, infrequent and ex‐users with polydrug and non‐using controls CJA Morgan, L Muetzelfeldt, HV Curran Addiction 104 (1), 77-87, 2009 | 205 | 2009 |
| Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial TP Freeman, C Hindocha, G Baio, NDC Shaban, EM Thomas, D Astbury, ... The Lancet Psychiatry 7 (10), 865-874, 2020 | 180 | 2020 |
Tom P FreemanReader, Addiction and Mental Health Group, Department of Psychology, University of BathVerified email at bath.ac.uk
